Share：
Share this content in WeChat
X
[Chinese] [PDF] 48 1
• Review •
Research progress on MRI radiomics in predicting the efficacy of neoadjuvant chemotherapy for breast cancer
LI Yuzhu  LIANG Yun  ZHAO Wenhui  LEI Junqiang 

DOI:10.12015/issn.1674-8034.2026.05.029.


[Abstract] The incidence and mortality rates of Breast Cancer (BC) currently rank first among malignant tumors in women. In recent years, Neoadjuvant Chemotherapy (NAC) has been widely used in the treatment of breast cancer. It has been shown to be effective in reducing tumor size, increasing the chances of surgery for patients, and assisting clinicians in identifying non-responsive cases. However, due to tumor heterogeneity and individual differences, not all patients can benefit from NAC. Thus, an accurate and objective evaluation of NAC efficacy is of paramount importance for informing individualized treatment planning in the subsequent phase. Currently, Magnetic Resonance Imaging (MRI) is widely favored for its non-invasive nature, multi-parameter capability, multi-sequence feature, and high soft-tissue resolution, thereby playing a pivotal role in the diagnosis, treatment and prognostic assessment of breast cancer. With the continuous development of high-precision diagnosis and treatment technologies, breast MRI radiomics has shown increasingly significant potential in the fields of preoperative diagnosis and prognosis prediction. This article reviews the progress of MRI image-based radiomics in predicting the efficacy of NAC for breast cancer. It also identifies the limitations of current research and explores future research directions, aiming to offer insights into precision diagnosis and treatment strategies for breast cancer.
[Keywords] breast cancer；neoadjuvant chemotherapy；magnetic resonance imaging；radiomics；therapeutic effect

LI Yuzhu1, 2   LIANG Yun1, 2   ZHAO Wenhui1   LEI Junqiang2*  

1 The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

2 Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

Corresponding author: LEI J Q, E-mail: leijq2011@126.com

Conflicts of interest   None.

Received  2026-01-26
Accepted  2026-04-14
DOI: 10.12015/issn.1674-8034.2026.05.029
DOI:10.12015/issn.1674-8034.2026.05.029.

[1]
XU J J, TAO J N, WANG X J, et al. Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domain Ⅳ in breast cancer[J]. China Pharm, 2024, 35(5): 635-640. DOI: 10.6039/j.issn.1001-0408.2024.05.22.
[2]
HU M T, CHEN J X. Effect of circular RNA hsacirc0000231 interacting with HnRNPK on proliferation, migration, and apoptosis in breast cancer[J]. J Army Med Univ, 2022, 44(12): 1207-1220. DOI: 10.16016/j.2097-0927.202204125.
[3]
BRITT K L, CUZICK J, PHILLIPS K A. Key steps for effective breast cancer prevention[J]. Nat Rev Cancer, 2020, 20(8): 417-436. DOI: 10.1038/s41568-020-0266-x.
[4]
LIU Z Y, KUO C F. Artificial intelligence-driven personalized medicine[J]. Hand Clin, 2026, 42(1): 65-74. DOI: 10.1016/j.hcl.2025.08.008.
[5]
LOI S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine[J]. Ann Oncol, 2019, 30(8): 1183-1184. DOI: 10.1093/annonc/mdz201.
[6]
LI B, KANG Z Q, MA Y Y, et al. Habitat radiomics based on pre-treatment DCE-MRI images for predicting pathological complete response(pCR) in invasive breast cancer after neoadjuvant chemotherapy[J]. J Clin Radiol, 2025, 44(7): 1211-1218. DOI: 10.13437/j.cnki.jcr.2025.07.005.
[7]
XIA K J, TANG N, WEI Y J, et al. Analysis of factors influencing pathologic complete response and its correlation with prognosis in HER2-low breast cancer[J]. Med J Chin People's Liberation Army, 2025, 50(9): 1129-1137. DOI: 10.11855/j.issn.0577-7402.1142.2025.0627.
[8]
TANG X, DU Y. Research progress of imaging method in predicting pathological complete remission of axillary lymph nodes after neoadjuvant therapy for breast cancer[J]. Radiol Pract, 2024, 39(5): 694-698. DOI: 10.13609/j.cnki.1000-0313.2024.05.022.
[9]
WANG H, MAO X Y. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer[J/OL]. Drug Des Devel Ther, 2020, 14: 2423-2433 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/32606609/. DOI: 10.2147/DDDT.S253961.
[10]
GEYER C E, SIKOV W M, HUOBER J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial[J]. Ann Oncol, 2022, 33(4): 384-394. DOI: 10.1016/j.annonc.2022.01.009.
[11]
JANG M K, PARK S, PARK C, et al. Body composition change during neoadjuvant chemotherapy for breast cancer[J/OL]. Front Oncol, 2022, 12: 941496 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/36091109/. DOI: 10.3389/fonc.2022.941496.
[12]
WANG H T, YU T, XU S. Research progress on the application of MRI radiomics in neoadjuvant chemotherapy for breast cancer[J]. J China Clin Med Imaging, 2023, 34(12): 892-896. DOI: 10.12117∕jccmi.2023.12.012.
[13]
LI X G, TIAN J, ZHANG C L, et al. Overview of MRI-based radiomics in breast cancer diagnosis and treatment[J]. Chin J Magn Reson Imaging, 2024, 15(7): 196-203. DOI: 10.12015/issn.1674-8034.2024.07.033.
[14]
WASIF N, GARREAU J, TERANDO A, et al. MRI versus ultrasonography and mammography for preoperative assessment of breast cancer[J]. Am Surg, 2009, 75(10): 970-975.
[15]
GRUBER I V, RUECKERT M, KAGAN K O, et al. Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer[J/OL]. BMC Cancer, 2013, 13(1): 328 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/23826951/. DOI: 10.1186/1471-2407-13-328.
[16]
SARDANELLI F, BOETES C, BORISCH B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group[J]. Eur J Cancer, 2010, 46(8): 1296-1316. DOI: 10.1016/j.ejca.2010.02.015.
[17]
CONTI A, DUGGENTO A, INDOVINA I, et al. Radiomics in breast cancer classification and prediction[J/OL]. Semin Cancer Biol, 2021, 72: 238-250 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/32371013/. DOI: 10.1016/j.semcancer.2020.04.002.
[18]
LIN Y Y, WANG J F, LI M Z, et al. Prediction of breast cancer and axillary positive-node response to neoadjuvant chemotherapy based on multi-parametric magnetic resonance imaging radiomics models[J/OL]. Breast, 2024, 76: 103737 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/38696854/. DOI: 10.1016/j.breast.2024.103737.
[19]
O'DONNELL J P M, GASIOR S A, DAVEY M G, et al. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: a systematic review and network meta-analysis[J/OL]. Eur J Radiol, 2022, 157: 110561 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/36308849/. DOI: 10.1016/j.ejrad.2022.110561.
[20]
ZHANG L, SHEN M Y, ZHANG D Y, et al. Radiomics nomogram based on dual-sequence MRI for assessing ki-67 expression in breast cancer[J]. J Magn Reson Imaging, 2024, 60(3): 1203-1212. DOI: 10.1002/jmri.29149.
[21]
BALTZER P, MANN R M, IIMA M, et al. Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group[J]. Eur Radiol, 2020, 30(3): 1436-1450. DOI: 10.1007/s00330-019-06510-3.
[22]
SCHEEL J R, KIM E, PARTRIDGE S C, et al. MRI, clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer: ACRIN 6657 trial[J]. AJR Am J Roentgenol, 2018, 210(6): 1376-1385. DOI: 10.2214/AJR.17.18323.
[23]
TOFTS P S, BERKOWITZ B, SCHNALL M D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model[J]. Magn Reson Med, 1995, 33(4): 564-568. DOI: 10.1002/mrm.1910330416.
[24]
WANG W W, LIU Y C, LI Y, et al. Feasibility study of DCE-MRI in predicting pathological complete remission of breast cancer after NAC treatment[J]. Chin J CT MRI, 2024, 22(7): 114-117. DOI: 10.3969/j.issn.1672-5131.2024.07.036.
[25]
SUN H X, ZHANG R Z, ZHOU C W, et al. Early prediction of response to neoadjuvant chemotherapy using quantitative dynamic contrast-enhanced magnetic resonance imaging in locally advanced breast cancer[J]. Oncoradiology, 2020, 29(2): 127-133. DOI: 10.19732/j.cnki.2096-6210.2020.02.010.
[26]
TONG Y, MI N, ZHANG R, et al. Quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging to evaluate the effect and correlation of neoadjuvant chemotherapy for breast cancer[J]. Chin J Gerontol, 2020, 40(16): 3410-3414. DOI: 10.3969/j.issn.1005-9202.2020.16.016.
[27]
SUROV A, PECH M, MEYER H J, et al. Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study[J/OL]. Cancer Imaging, 2022, 22(1): 68 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/36494872/. DOI: 10.1186/s40644-022-00501-2.
[28]
WEN L, NEWITT D C, WILMES L J, et al. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL[J]. J Magn Reson Imaging, 2019, 50(6): 1742-1753. DOI: 10.1002/jmri.26770.
[29]
WANG X L, HUA H, HAN J Q, et al. Evaluation of multiparametric MRI radiomics-based nomogram in prediction of response to neoadjuvant chemotherapy in breast cancer: a two-center study[J/OL]. Clin Breast Cancer, 2023, 23(6): e331-e344 [2026-01-25]. https://www.clinical-breast-cancer.com/article/S1526-8209(23)00134-9/abstract. DOI: 10.1016/j.clbc.2023.05.010.
[30]
YU Y M, WANG Z B, WANG Q, et al. Radiomic model based on magnetic resonance imaging for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer patients[J/OL]. Front Oncol, 2023, 13: 1249339 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/38357424/. DOI: 10.3389/fonc.2023.1249339.
[31]
YOSHIDA K, KAWASHIMA H, KANNON T, et al. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using radiomics of pretreatment dynamic contrast-enhanced MRI[J/OL]. Magn Reson Imaging, 2022, 92: 19-25 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/35636571/. DOI: 10.1016/j.mri.2022.05.018.
[32]
CHEN X G, CHEN X F, YANG J D, et al. Combining dynamic contrast-enhanced magnetic resonance imaging and apparent diffusion coefficient maps for a radiomics nomogram to predict pathological complete response to neoadjuvant chemotherapy in breast cancer patients[J]. J Comput Assist Tomogr, 2020, 44(2): 275-283. DOI: 10.1097/RCT.0000000000000978.
[33]
YAN C, QIN S G, LIU Y J, et al. Construction of prognostic prediction models for breast cancer patients based on nomo-gram and decision tree with least absolute shrinkage and selection operator regression [J/OL]. J Mod Oncol [2025-11-21]. https://link.cnki.net/urlid/61.1415.r.20250917.2100.010.
[34]
YE K N, LIAO X H, YANG W P, et al. A novel nomogram to predict pathological complete response in breast cancer patients and identify candidates who might omit surgery: a large cohort study[J/OL]. Cancer Med, 2025, 14(21): e71372 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/41204791/. DOI: 10.1002/cam4.71372.
[35]
LIU Z Y, LI Z L, QU J R, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study[J]. Clin Cancer Res, 2019, 25(12): 3538-3547. DOI: 10.1158/1078-0432.CCR-18-3190.
[36]
BRAMAN N M, ETESAMI M, PRASANNA P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI[J/OL]. Breast Cancer Res, 2017, 19(1): 57 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/term=DOI%3A+10.1186%2Fs13058-017-0846-1. DOI: 10.1186/s13058-017-0846-1.
[37]
CORTAZAR P, ZHANG L J, UNTCH M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. DOI: 10.1016/S0140-6736(13)62422-8.
[38]
VON MINCKWITZ G, UNTCH M, BLOHMER J U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012, 30(15): 1796-1804. DOI: 10.1200/JCO.2011.38.8595.
[39]
ZHANG J P, WU Q, LEI P, et al. MRI-based radiomics models for early predicting pathological response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis[J/OL]. J Appl Clin Med Phys, 2025, 26(10): e70296 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/41094242/. DOI: 10.1002/acm2.70296.
[40]
XIONG Q Q, ZHOU X Z, LIU Z Y, et al. Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy[J]. Clin Transl Oncol, 2020, 22(1): 50-59. DOI: 10.1007/s12094-019-02109-8.
[41]
GUO L C, DU S Y, GAO S, et al. Delta-radiomics based on dynamic contrast-enhanced MRI predicts pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy[J/OL]. Cancers, 2022, 14(14): 3515 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/35884576/. DOI: 10.3390/cancers14143515.
[42]
CABALLO M, SANDERINK W B G, HAN L Y, et al. Four-dimensional machine learning radiomics for the pretreatment assessment of breast cancer pathologic complete response to neoadjuvant chemotherapy in dynamic contrast-enhanced MRI[J]. J Magn Reson Imaging, 2023, 57(1): 97-110. DOI: 10.1002/jmri.28273.
[43]
HENNESSY B T, HORTOBAGYI G N, ROUZIER R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy[J]. J Clin Oncol, 2005, 23(36): 9304-9311. DOI: 10.1200/JCO.2005.02.5023.
[44]
SAXENA N, HARTMAN M, AZIZ R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study[J]. Eur J Cancer, 2011, 47(8): 1186-1192. DOI: 10.1016/j.ejca.2010.12.009.
[45]
LUCCI A, MCCALL L M, BEITSCH P D, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011[J]. J Clin Oncol, 2007, 25(24): 3657-3663. DOI: 10.1200/JCO.2006.07.4062.
[46]
GAN L Y, MA M M, LIU Y H, et al. A clinical-radiomics model for predicting axillary pathologic complete response in breast cancer with axillary lymph node metastases[J/OL]. Front Oncol, 2021, 11: 786346 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/34993145/. DOI: 10.3389/fonc.2021.786346.
[47]
FENG W, QU M M, XIONG Y H, et al. Combining intratumoral and peritumoral multimodality magnetic resonance imaging (MRI) to predict the expression level of human epidermal growth factor receptor-2 (HER-2) in breast cancer[J/OL]. Clin Radiol, 2025, 90: 107019 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/40939277/. DOI: 10.1016/j.crad.2025.107019.
[48]
CHEN S Y, ZHONG Z D, CHEN Y X, et al. Prediction of lymphovascular invasion in invasive breast cancer via intratumoral and peritumoral multiparametric magnetic resonance imaging machine learning-based radiomics with Shapley additive explanations interpretability analysis[J]. Quant Imaging Med Surg, 2025, 15(9): 7833-7846. DOI: 10.21037/qims-2024-2685.
[49]
ZHENG G Y, PENG J X, SHU Z Y, et al. Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms[J/OL]. J Cancer Res Clin Oncol, 2024, 150(3): 147 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/38512406/. DOI: 10.1007/s00432-024-05680-y.
[50]
XU H M, DAI Y, MA Y Z, et al. MR T1WI intratumoral and peritumoral radiomics combined with clinical features for predicting effect of neoadjuvant chemotherapy for breast cancer[J]. Chin J Med Imaging Technol, 2023, 39(10): 1520-1525. DOI: 10.13929/j.issn.1003-3289.2023.10.016.
[51]
XIE T W, GONG J, ZHAO Q F, et al. Development and validation of peritumoral vascular and intratumoral radiomics to predict pathologic complete responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer[J/OL]. BMC Med Imaging, 2024, 24(1): 136 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/38844842/. DOI: 10.1186/s12880-024-01311-7.
[52]
Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association, SHAO Z M. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association(2024 edition)[J]. China Oncol, 2023, 33(12): 1092-1186. DOI: 10.19401/j.cnki.1007-3639.2023.12.004.
[53]
LYU L, LI H Y, LU K F, et al. PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy[J]. Br J Cancer, 2024, 130(3): 394-405. DOI: 10.1038/s41416-023-02523-4.
[54]
ZHANG X Y, DING Y Y, LI Z L, et al. The value of synthetic MRI quantitative parameters in the peritumoral region for evaluating the efficacy of neoadjuvant chemotherapy in breast cancer[J]. J Clin Radiol, 2025, 44(6): 1010-1014. DOI: 10.13437/j.cnki.jcr.2025.06.007.
[55]
ZHAO S Q, LI Y F, NING N, et al. Association of peritumoral region features assessed on breast MRI and prognosis of breast cancer: a systematic review and meta-analysis[J]. Int J Med Radiol, 2024, 47(6) DOI: 10.19300/j.2024.e0914.
[56]
WANG M F, CHEN W J, REN R P, et al. Comparative analysis of multi-zone peritumoral radiomics in breast cancer for predicting NAC response using ABVS-based deep learning models[J/OL]. Front Oncol, 2025, 15: 1586715 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/40438687/. DOI: 10.3389/fonc.2025.1586715.
[57]
ZHU Y, ZHANG S N, WEI W, et al. Intra- and peritumoral radiomics nomogram based on DCE-MRI for the early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer[J/OL]. Front Oncol, 2025, 15: 1561599 [2026-01-25]. https://pubmed.ncbi.nlm.nih.gov/40535128/. DOI: 10.3389/fonc.2025.1561599.

PREV Advances in the application of flexible MRI coils in head and neck imaging
NEXT Advances in the application of ultrafast dynamic contrast-enhanced MRI in the diagnosis and treatment of breast cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn